Metastasis-directed radiotherapy without systemic therapy demonstrated an improved safety profile vs immunotherapy and tyrosine kinase inhibitors.
JSKN003 demonstrated tolerability and antitumor activity in heavily pretreated HER2-positive breast cancer.
KIM-1 levels have shown the ability to predict therapeutic benefit in patients with renal cell carcinoma.
The FDA issued a CRL to the application for glofitamab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.
Luspatercept plus a concomitant JAK inhibitor didn’t meet the primary end point of 12-week RBC transfusion independence in myelofibrosis-associated anemia.
PF-07248144 is a first-in-class selective inhibitor of KAT6A and KAT6B that has displayed the ability to suppress ER expression in a preclinical study.
Mats Jerkeman, MD, discusses long-term follow-up data of the Nordic MCL2 and MCL3 trials in younger patients with mantle cell lymphoma.
High levels of CD163-positive TAMs and exhausted CD8-positive TILs could potentially affect efficacy results in metastatic RCC by reprogramming TAMs.
JSKN003 demonstrated tolerability and antitumor activity in heavily pretreated HER2-positive breast cancer.
In an OncLive Peer Exchange, expert investigators convened to discuss the treatment landscape of early-stage NSCLC from a multidisciplinary perspective.
Treatment with belzutifan increased the time without progression or toxicity vs everolimus in patients with advanced RCC.
